Aspira Women's Health Inc.

Aspira Women's Health Inc. presents a distressed capital structure characterized by negative total equity of $6.2 million and a working capital deficit of $1.8 million as of Q1 2026. The company holds $1.3 million in cash and equivalents against $1.1 million in total liabilities, resulting in a current ratio of 0.68, which indicates an inability to cover short-term obligations with current assets. Long-term debt stands at $0.98 million, while short-term debt is $0.24 million. The negative equity position is driven by an accumulated deficit of approximately $543.5 million, reflecting years of operational losses. The company reports a negative EV/EBITDA of -2.27 and a negative return on assets of -2.51, signaling that asset utilization is currently destroying value. The market capitalization is $17.9 million, implying an EV/Revenue multiple of 1.92, which is typical for small-cap biotech firms with uncertain cash flows but high dilution risk.

Profitability metrics are mixed due to non-cash accounting items. While the company reported a net income of $0.68 million in Q1 2026, this was driven by a $3.1 million gain from the change in fair value of warrant liabilities, masking an operating loss of $2.2 million. Gross profit was $1.07 million on revenue of $1.97 million, yielding a gross margin of approximately 54.4%. However, operating expenses, including research and development and general and administrative costs, far exceeded gross profit. The return on equity is reported as 2.06, but this metric is distorted by the negative equity base and is not indicative of sustainable profitability. The company relies heavily on financing activities to fund operations, as operating cash flow was negative $0.36 million in Q1 2026.

The company operates as a single reportable segment, focusing exclusively on molecular diagnostics for women's health. Revenue is derived primarily from the United States, with no significant international exposure disclosed in the segment data. The business model depends on partnerships with large reference laboratories, notably Quest Diagnostics, for specimen collection and processing. This concentration creates dependency risk, as the company's commercial reach is tied to the distribution networks and contractual terms of these third-party partners. The lack of geographic diversification means the company is fully exposed to US healthcare reimbursement policies and regulatory changes.

Growth trajectory remains flat to declining in absolute terms. Q1 2026 revenue of $1.97 million represents a modest increase from the prior year period, but the company has struggled to achieve scale. The historical context shows persistent net losses, with Q1 2025 reporting a net loss of $1.85 million. The company has not demonstrated consistent revenue growth sufficient to offset its high fixed cost structure. The reliance on equity financing to fund operations suggests that organic growth is insufficient to support the business model without external capital injection.

Risk factors are elevated across all categories. Liquidity risk is high, with the company explicitly referencing going-concern language in its filings due to the working capital deficit and accumulated losses. Dilution risk is also high, evidenced by the significant difference between basic shares outstanding (43.5 million) and diluted shares outstanding (45.8 million), as well as the presence of numerous warrant series and convertible notes. The company has engaged in multiple equity offerings, including At-the-Market (ATM) offerings and private placements, which have historically diluted existing shareholders. The fair value adjustments of warrants introduce volatility into the income statement, making earnings less predictable.

Recent events highlight the company's ongoing capital raising efforts. In Q1 2026, the company issued common stock under its 2024 At-the-Market Offering Agreement and settled convertible notes with equity. The company also entered into a new Equity Line of Credit Agreement with Lincoln Park Capital Fund in late 2025, providing access to additional capital but at the cost of further potential dilution. The filing of an 8-K with material items 1.01 and 2.03 indicates significant corporate actions, likely related to these financing arrangements. The company continues to rely on these instruments to maintain liquidity, underscoring the precarious nature of its financial position.

Aspira's FY2025 operating loss narrowed significantly to $7.9 million, indicating improved operational efficiency compared to prior periods.

The company maintains a best-in-class debt-to-equity ratio of -0.2, signaling minimal leverage risk relative to peers.

Aspira's return on equity of 2.06% ranks as best-in-class within the biotechnology cohort of 574 companies.

Long-term debt decreased to $1.04 million in FY2025, demonstrating a consistent trend of deleveraging over the three-year period.

The company faces high liquidity risk, threatening its ability to meet short-term obligations without additional capital raises.

High dilution risk exists as the company continues to operate with negative net income and negative free cash flow.

Revenue growth remains stagnant with a negligible 0.2% CAGR from FY2023 to FY2025, limiting top-line expansion potential.

Cash conversion efficiency is in the bottom quartile of its cohort, indicating poor translation of earnings into cash.

The company reported a negative book value of -$6.5 million, suggesting accumulated losses have eroded shareholder equity.

Revenue $2.0M; Operating income -$2.2M.

• ▍Revenue $2.0M
• ▍Operating income -$2.2M
• ▍Net margin 34.4%

Revenue $7.0M; Operating income -$6.6M.

• ▍Revenue $7.0M
• ▍Operating income -$6.6M
• ▍Net margin -134.7%

Revenue $4.7M; Operating income -$5.0M.

• ▍Revenue $4.7M
• ▍Operating income -$5.0M
• ▍Net margin -96.5%

Revenue $9.2M; Operating income -$7.9M.

• ▍Revenue $9.2M
• ▍Operating income -$7.9M
• ▍Net margin -138.7%

Revenue $9.2M; Operating income -$16.3M.

• ▍Revenue $9.2M
• ▍Operating income -$16.3M
• ▍Net margin -142.6%

Revenue $9.2M; Operating income -$16.3M.

• ▍Revenue $9.2M
• ▍Operating income -$16.3M
• ▍Net margin -142.6%

Revenue $9.2M; Operating income -$18.9M.

• ▍Revenue $9.2M
• ▍Operating income -$18.9M
• ▍Net margin -182.3%

Revenue $9.2M; Operating income -$18.9M.

• ▍Revenue $9.2M
• ▍Operating income -$18.9M
• ▍Net margin -182.3%